Increased Frequency of Infections at the End of the IVIG Dosing Cycle: Effect Characterization from Three Phase III Studies

Martin Bexon(Bexon Clinical Consulting (United States)), O. Zenker(CSL (Switzerland)), Mikhail Rojavin(CSL (United States)), Jeffrey S. Baggish(CSL (United States)), M. S. Berger(Duke University)

Journal of Allergy and Clinical Immunology

February 1, 2012

10.1016/j.jaci.2011.12.286

Cited by 4

Related Papers

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

|Nature|2020|2.1k

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

|Blood|1999|456

Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin Immunoconjugate

|Blood|1999|439

Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to <i>bcl-2</i> .

|The Journal of Immunology|1993|336

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

|Leukemia|2002|224